title: Outpatient percutaneous central venous access in cancer patients.
abstract: A 1-year experience of percutaneous subclavian catheterization in outpatients with cancer was reviewed to document reliability, safety, and cost. There were 763 catheter insertions attempted with prospective documentation of complications in 664 consecutive patients. Catheter insertion was successful in 722 attempts (95%). There were only 13 pneumothoraces (2%). Thirty catheters required repositioning (4%). The average catheter duration was 191 days (range: 0 to 892 days). Fifty-six catheters (8%) were removed because of suspected infection. Documented catheter sepsis occurred in 21 patients (3%); catheter site infection occurred in 8 patients (1%). Thus, only 0.22 infections per catheter year occurred during this 382 catheter-year experience. The estimated cost of catheter insertion was $562, which is one-third the estimated cost for tunneled catheters ($1,403) and for reservoir devices ($1,738). In our experience, percutaneous subclavian catheterization is a reliable, cost-effective method compared with tunneled or reservoir devices, with an equivalent incidence of catheter-related infections. The cornerstone of our success with this program is a staff dedicated to catheter care and intensive patient education. In centers where a large number of patients require central venous access, percutaneous catheterization should be the technique of choice.
authors: Department of General Surgery, University of Texas M. D. Anderson Cancer Center, Houston.
authors: J R
authors: JR
authors: Broadwater
authors: M A
authors: MA
authors: Henderson
authors: J L
authors: JL
authors: Bell
authors: M J
authors: MJ
authors: Edwards
authors: G J
authors: GJ
authors: Smith
authors: D R
authors: DR
authors: McCready
authors: R S
authors: RS
authors: Swanson
authors: M E
authors: ME
authors: Hardy
authors: R R
authors: RR
authors: Shenk
authors: M
authors: M
authors: Lawson
mesh_terms: D000553:Ambulatory Care; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002173:Cancer Care Facilities; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000191:economics / Q000379:methods; D003365:Costs and Cost Analysis; D006801:Humans; D007239:Infections / Q000453:epidemiology; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013350:Subclavian Vein; D013781:Texas; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents